Neurology and Neurosurgery

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Detection of Vascular and Inflammatory Plasma Biomarkers in Patients Diagnosed with Obstructive Sleep Apnea and MRI-defined Cerebral Small Vessel Disease

   Jacksonville, Fla.

   The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) and pre-existing imaging evidence of Cerebral Small Vessel Disease (CSVD).

2. Image-based Mapping of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

3. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden

   Jacksonville, Fla., Rochester, Minn., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).

4. Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. 

5. Metastatic Tumor Research and Outcomes Network

   Rochester, Minn.

   The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).

6. Electrophysiological Biomarkers for Parkinson's Disease

   Scottsdale/Phoenix, Ariz.

   This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline.

7. A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease

   Jacksonville, Fla.

   The purpose of this study is to characterize and study the relationship of the clinical risk factors and predictors of seizures and epilepsy in patients with Early Onset Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG.

8. A Registry to Follow Long-Term Outcomes for Mother and Child Pairs After Fetal Surgery for Spina Bifida

   Rochester, Minn.

   The purpose of this study is to form a registry of data on the long term physical and mental health outcomes of the mother and child following fetal surgical repair for spina bifida.

9. Brain Health and Dementia Prevention Registry

   Jacksonville, Fla.

   The purpose of this study is to create a registry of patients having a clinical diagnosis and collect demographics, cognitive testing, blood and cerebrospinal fluid so that biomarkers and genetic difference can be found in different patient groups.

10. Inherited Muscle Diseases Repository

    Rochester, Minn.

    To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect. To access residual muscle specimens from diagnostic muscle biopsies obtained as part of the routine medical care. The biospecimens will be used to better understanding the underlying molecular defects and mechanisms of muscle diseases.